JNJ News & Events

Johnson & Johnson announced new long-term 52-week data from the Phase 3 Iconic-Advance 1 and 2 and Iconic-Lead studies, which assessed the efficacy and safety of Icotyde in the treatment of patients with moderate-to-severe plaque psoriasis. Icotyde is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are being presented at the 2026 American Academy of Dermatology, AAD, Annual Meeting. Icotyde achieved high levels of complete skin clearance up to Week 52 with no new safety signals: In the Icotyde treatment arms, rates of completely clear skin increased from 41% to 49% and 33% to 48% from Week 24 to Week 52 in Advance-1 and 2, respectively. Patients who switched from placebo to Icotyde at Week 16 achieved similar rates of complete skin clearance by Week 52 as those who were treated with Icotyde for the full 52 weeks. The Icotyde adverse event profile through Week 52 was consistent with that observed through Weeks 16 and 24, and no new safety signal was identified through Week 52. Icotyde overall adverse event and infection rates were lower than deucravacitinib through Week 24.

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.JONES ACT:President Donald Trump has issued a short-term waiver of the Jones Act, authorizing foreign-flagged vessels to transport a range of commodities between U.S. ports for the next 60 days. "President Trump's decision to issue a 60-day Jones Act waiver is just another step to mitigate the short-term disruptions to the oil market as the U.S. military continues meeting the objectives of Operation Epic Fury. The Administration remains committed to continuing to strengthen our critical supply chains," White House Press Secretary Karoline Leavitt stated.QUARTERLY REPORTING:The Securities and Exchange Commission is preparing a proposal to eliminate the quarterly earnings report requirement and instead give companies the option to share results twice a year, people familiar with the matterThe Wall Street Journal's Corrie Driebusch, adding that the regulator could publish the proposal as soon as next month.TRUMPRX:President Trump and top federal health officials have repeatedly claimed that their new website, TrumpRx, offers Americans the world's lowest prices on prescription drugs, but that is not true, according to a review by The New York Times and the German news organizations Suddeutsche Zeitung, NDR and WDR, The NYT's Rebecca Robbins. The drugs listed on TrumpRx can cost American patients up to hundreds or thousands of dollars, while a patient walking into a German pharmacy pays next to nothing, Robbins writes. Publicly traded companies in the space include AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Rocheand Sanofi.NATIONAL CYBERSECURITY STRATEGY:Quantum Cybersaid, "On March 10, 2026, the White House released a sweeping National Cybersecurity Strategy document under the direction of President Donald Trump, articulating six foundational pillars intended to defend the safety, security, and prosperity of the American people in cyberspace. The strategy represents one of the most comprehensive federal policy commitments to cyber defense in recent history and signals a significant expansion of investment and regulatory focus in both cybersecurity and quantum computing."Among the key pillars of the Trump cybersecurity framework are: proactively detecting and defeating adversarial cyber actors before they breach U.S. networks; streamlining cyber regulations to reduce compliance burdens and align the private sector with government objectives; accelerating the adoption of post-quantum cryptography, zero-trust architecture, and secure cloud infrastructure across national security systems; prioritizing U.S.-developed technologies over adversarial products; building a robust domestic cyber workforce; and promoting the security of cryptocurrencies and blockchain technologies through the adoption of post-quantum cryptographic standards."Quantum Cyber views the White House's strategy as a direct validation of the Company's core business thesis. The convergence of quantum computing and cybersecurity - two domains at the center of the Trump Administration's framework - represents one of the most significant growth opportunities in the technology sector over the coming decade. The Company believes its name, focus, and developing capabilities place it at the intersection of both priority areas identified by the federal government. Building on the momentum of the Trump Administration's cybersecurity framework, Quantum Cyber's management team is actively evaluating a pipeline of strategic acquisition candidates operating in quantum computing, post-quantum cryptography, zero-trust network architecture, and adjacent cybersecurity disciplines."The Company believes that a targeted acquisition strategy will accelerate its ability to build an operationally active platform with measurable revenue potential in sectors directly aligned with U.S. national security priorities. The Company is currently conducting preliminary due diligence on several opportunities and is engaged in discussions with potential targets. While no definitive agreements have been reached and there can be no assurance that any transaction will be consummated, management is cautiously optimistic about the quality of the pipeline and the timeliness of the strategic window created by the current federal policy environment. The Company intends to provide further updates as discussions progress."